Apixaban Patent Portfolio Details
A comprehensive database for apixaban's patent portfolio would track patents related to the drug's active pharmaceutical ingredient, its formulations, and methods of use. These patents are crucial for understanding market exclusivity and potential generic entry timelines. DrugPatentWatch.com offers such a database, providing detailed information on the patent landscape for many drugs, including apixaban [1].
When Does Apixaban's Key Patent Protection End?
The primary patent for apixaban (Eliquis) is U.S. Patent No. 7,399,758, which covers the compound itself. While its expiration date has passed in some regions, secondary patents covering specific formulations and methods of use can extend market exclusivity. These secondary patents are critical for preventing generic competition even after the primary patent expires [2].
Why Are Companies Challenging Apixaban Patents?
Companies developing generic versions of apixaban frequently challenge existing patents. These challenges aim to invalidate or circumvent patents, clearing the way for their products to enter the market sooner. Litigation surrounding these patents is common and can significantly impact the drug's market dynamics and availability of lower-cost alternatives [3].
How Do Apixaban Patents Affect Generic Entry?
The strength and breadth of apixaban's patent portfolio directly influence when generic versions can be launched. Patents for the active ingredient, specific crystalline forms, dosing regimens, and manufacturing processes can all create barriers to entry. A robust patent strategy by the innovator company can prolong market exclusivity, while successful patent challenges by generic manufacturers can accelerate competition [4].
What Are the Risks Associated with Apixaban Patents?
For patients and healthcare systems, the main risk associated with extensive patent protection is the continued high cost of the drug. Delays in generic entry mean that more affordable treatment options are unavailable for longer periods. Conversely, for the innovator company, the risk lies in successful patent challenges that could lead to premature generic competition and loss of market share [5].
How Does Apixaban's Patent Situation Compare to Other Anticoagulants?
The patent landscape for apixaban is part of a broader trend in the pharmaceutical industry where innovator drugs benefit from multi-layered patent protection extending exclusivity. Drugs like rivaroxaban (Xarelto) and dabigatran (Pradaxa) also have complex patent portfolios. Understanding these patent strategies helps to predict market exclusivity periods and the eventual introduction of generic alternatives across the class of direct oral anticoagulants (DOACs) [6].
Who Manufactures Apixaban?
Apixaban is primarily manufactured and marketed by Bristol Myers Squibb and Pfizer under the brand name Eliquis. Generic versions will be produced by various pharmaceutical companies once patent protections expire and are successfully challenged [7].
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/drug/apixaban/patents
[3] https://www.drugpatentwatch.com/drug/apixaban/litigation
[4] https://www.drugpatentwatch.com/drug/apixaban/exclusivity
[5] https://www.drugpatentwatch.com/drug/apixaban/alternatives
[6] https://www.drugpatentwatch.com/drug/rivaroxaban/patents
[7] https://www.drugpatentwatch.com/drug/apixaban/manufacturers